Eli Lilly and Sankyo’s CS-747 / Prasugrel for Acute Coronary Syndrome
October 25, 2004 by admin · Leave a Comment
On October 25, 2004 Eli Lilly and Company and Sankyo Company announced that a Phase 3 clinical trial comparing the antiplatelet agents prasugrel and Plavix™ is scheduled to begin later this year. The study, known as TRITON-TIMI 38, will include a reported 13,000 patients who are suffering acute coronary syndromes (heart attacks or unstable angina) and undergoing a percutaneous coronary intervention (PCI) like angioplasty or coronary artery stenting. The company has indicated that the main focus of the study is to compare the efficacy of prasugrel with that of Plavix in the prevention of heart attack, stroke and death in patients who undergo PCI. The outcomes of post procedure bleeding, recurrent heart-related chest pain (ischemia) and the need for additional procedures to restore blood flow (urgent target revascularization) will also be examined. BioHorizon has assigned prasugrel an efficacy score of 75/100 for its Phase 3 stage of development and a 42/100 value for the burden of illness associated with the approximately 560, 000 PCI’s performed in the United States each year.
Prasugrel is an oral antiplatelet drug that may prevent platelet activation by blocking adenosine diphosphate receptors on the platelet surface. When activated, these receptors allow for a protein in the blood known as fibrin to link platelets together, creating a ‘plug’ or ‘clump’ of platelets that can produce a critical vessel blockage and cause a heart attack. Other anti-platelet treatments currently available include ASA, the thienopyridines-clopidogrel (Plavix), and ticlopidine as well as the glycoprotein IIb/IIIa inhibitors abciximab and tirafibrin. We have assigned prasugrel 50/100 for innovation as a new drug in an existing class of oral antiplatelet drugs.
BioHorizon believes that demand/diffusion parameters for oral anti-platelet drugs are increasing. Bristol Myers Squibb, the manufacturers of Plavix™, recently reported a 23% increase in U.S. prescriptions and a nine month total sales figure of in excess of 900 million dollars. Depending on the forthcoming efficacy and adverse event data, prasugrel could compete in this market. We have assigned this technology a demand/diffusion score of 20/100.
The overall BioHorizon Emerging Health Technology Impact Score is 47/100, currently placing prasugrel in our Moderate Impact Technology category. No preliminary assessment activities are recommended for health services clients at this time.
Technology Details
Target Disease / Indication: Acute Coronary Syndrome
Technology Classification: Drug
Body System: Cardiovascular System
Program Area: Medicine/Cardiology
Regulatory Status: Phase 3
BioHorizon Impact Score: 47/100 – Moderate Impact
